According to recent market information, **Kimberly-Clark's** international tissue unit has piqued overseas buyers' interest. The company is seeing a robust trading day, outperforming its competitors and its stock garnered the attention of **Avanza Fonder AB**, **Goldstone Financial Group**, **LCC** and others who purchased shares. Barclays has set a new price target for Kimberly-Clark at $132.00, while Citigroup lowered it to $118.00, signaling potentially contrasting views on the company's performance. In addition, the **Pension Protection Fund** board has bought 7,100 shares, displaying confidence in Kimberly-Clark's strategy. However, it's important to note that analysts' price target modifications have been mixed. The Q3 2024 earnings call highlighted strategic advancements in the market, leading to improved stock performance despite daily losses. Further, the company’s shares were sold by institutions like **Wright Investors Service Inc.** indicating mixed institutional interest. Meanwhile, Kimberly-Clark is also reportedly an appealing option for early retirement portfolios due to its stable dividend practice. The company has announced the dates for its Q4 2024 earnings release and analyst call. Ultimately, based on its upcoming earnings release and changes in shareholding, Kimberly-Clark appears to remain an interesting prospect for investors.
Kimberly-Clark Corp KMB News Analytics from Tue, 23 Apr 2024 07:00:00 GMT to Sat, 18 Jan 2025 20:32:00 GMT -
Rating 6
- Innovation 3
- Information 7
- Rumor -2
